Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Placebo-controlled, Dose-escalation Study of the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of LHF-535 (LHF-535-SDD) in Healthy Participants

Next Previous
X
Search
Trial Profile

A Double-blind, Placebo-controlled, Dose-escalation Study of the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of LHF-535 (LHF-535-SDD) in Healthy Participants

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LHF 535 (Primary)
  • Indications Lassa fever
  • Focus Adverse reactions
  • Sponsors Kineta

    • Most Recent Events

    • 31 Oct 2022 Results assessing Safety and Pharmacokinetics of LHF-535, a Potential Treatment for Lassa Fever, in Healthy Adults published in the Antimicrobial Agents and Chemotherapy published in the Antimicrobial Agents and Chemotherapy
    • 25 Mar 2021 According to a Kineta media release, clinical data from this study was presented by Sean Amberg (PhD, Director of Biodefense Initiatives at Kineta), at the International Conference on Antiviral Research (ICAR) Virtual Conference 2021.
    • 08 Jul 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top